文献速递血栓与止血

选择性抑制活化蛋白C抗凝活性可防止小鼠血友病性关节病

Selective inhibition of activated protein C anticoagulant activity protects against hemophilic arthropathy in mice.
PubMed 文献 · Blood · 2022-01-01

本研究在FVIII-/-小鼠中通过针刺诱导关节出血,比较阻断APC抗凝与信号活性的MPC1609单抗和仅阻断抗凝活性的MAPC1591单抗。结果显示仅MAPC1591显著减轻血友病性关节病严重程度,并抑制关节出血诱导的IL-6表达和血管渗漏,而MPC1609无显著效果,提示选择性抑制APC抗凝活性而不影响其细胞保护信号可能成为治疗血友病性关节病的替代方案。

要点

  • MAPC1591仅阻断APC抗凝活性,MPC1609同时抑制抗凝和信号活性
  • 两抗体体外抑制APC抗凝活性及纠正急性出血效果无显著差异
  • 仅MAPC1591显著减轻血友病性关节病严重程度并抑制IL-6和血管渗漏

核心结论

  • 选择性抑制APC抗凝活性而不损害其细胞保护信号的单克隆抗体,为治疗血友病性关节病提供了潜在替代方案。

研究设计与样本

  • FVIII-/-小鼠接受单剂同型对照mAb、MPC1609 mAb(抑制APC抗凝和信号特性)或MAPC1591 mAb(仅阻断APC抗凝活性)治疗,通过针刺损伤诱导关节出血,评估关节出血、关节直径变化及组织病理学。

主要发现

  • MPC1609与MAPC1591在体外抑制APC抗凝活性方面无显著差异,在纠正FVIII-/-小鼠隐静脉切开诱导的急性出血方面效果相当。
  • 给予MAPC1591而非MPC1609可显著降低血友病性关节病的严重程度。
  • MAPC1591抑制关节出血诱导的炎症细胞因子白细胞介素-6表达和关节血管渗漏,而MPC1609无显著效果。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recurrent spontaneous or trauma-related bleeding into joints in hemophilia leads to hemophilic arthropathy (HA), a debilitating joint disease. Treatment of HA consists of preventing joint bleeding by clotting factor replacement, and in extreme cases, orthopedic surgery. We recently showed that administration of endothelial cell protein C receptor (EPCR) blocking monoclonal antibodies (mAb) markedly reduced the severity of HA in factor VIII (FVIII)-/- mice. EPCR blocking inhibits activated protein C (APC) generation and EPCR-dependent APC signaling. The present study was aimed to define the role of inhibition of APC anticoagulant activity, APC signaling, or both in suppressing HA. FVIII-/- mice were treated with a single dose of isotype control mAb, MPC1609 mAb, that inhibits anticoagulant, and signaling properties of APC, or MAPC1591 mAb that only blocks the anticoagulant activity of APC. Joint bleeding was induced by needle puncture injury. HA was evaluated by monitoring joint bleeding, change in joint diameter, and histopathological analysis of joint tissue sections for synovial hypertrophy, macrophage infiltration, neoangiogenesis, cartilage degeneration, and chondrocyte apoptosis. No significant differences were observed between MPC1609 and MAPC1591 in inhibiting APC anticoagulant activity in vitro and equally effective in correcting acute bleeding induced by the saphenous vein incision in FVIII-/- mice. Administration of MAPC1591, and not MPC1609, markedly reduced the severity of HA. MAPC1591 inhibited joint bleed-induced inflammatory cytokine interleukin-6 expression and vascular leakage in joints, whereas MPC1609 had no significant effect. Our data show that an mAb that selectively inhibits APC's anticoagulant activity without compromising its cytoprotective signaling offers a therapeutic potential alternative to treat HA.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Magisetty J, Kondreddy V, Keshava S, et al. Selective inhibition of activated protein C anticoagulant activity protects against hemophilic arthropathy in mice. Blood. 2022. PMID: 35143636. doi:10.1182/blood.2021013119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。